Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Debrisoquine metabolism and CYP2D expression in marmoset liver microsomes.

Cooke BR, Bligh SW, Cybulski ZR, Ioannides C, Hall M.

Drug Metab Dispos. 2012 Jan;40(1):70-5. doi: 10.1124/dmd.111.041566. Epub 2011 Oct 5.

PMID:
21976620
2.

Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride).

Midgley I, Fitzpatrick K, Taylor LM, Houchen TL, Henderson SJ, Wright SJ, Cybulski ZR, John BA, McBurney A, Boykin DW, Trendler KL.

Drug Metab Dispos. 2007 Jun;35(6):955-67. Epub 2007 Mar 14.

PMID:
17360833
3.

Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450.

Hall M, Persiani S, Cheung YL, Matthews A, Cybulski ZR, Holding JD, Kapil R, D'Amato M, Makovec F, Rovati LC.

Biopharm Drug Dispos. 2004 May;25(4):163-76.

PMID:
15108219
4.

Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects.

Webber C, Roth A, Persiani S, Peard AJ, Makovec F, Kapil RP, John BA, Holding JD, D'amato M, Cybulski ZR, Chasseaud LF, Rovati LC.

Xenobiotica. 2003 Jun;33(6):625-41.

PMID:
12851039
5.

Determination of benzalkonium chloride by gas chromatography.

Cybulski ZR.

J Pharm Sci. 1984 Dec;73(12):1700-2.

PMID:
6527238

Supplemental Content

Loading ...
Support Center